Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -25.17% is 60% above its 5-year average of -63.00%, near the high end of its 5-year range (-148.55%–-25.17%).
34.68% above its 12-month average of -38.54%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.74%.
RETURN ON ASSETS (ROA)
-25.17%
RETURN ON ASSETS (ROA) AVG TTM
-38.54%
RETURN ON ASSETS (ROA) AVG 3Y
-43.55%
RETURN ON ASSETS (ROA) AVG 5Y
-63.00%
RETURN ON ASSETS (ROA) AVG 10Y
-71.62%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.68%
CURRENT VS 3Y AVG
+42.20%
CURRENT VS 5Y AVG
+60.05%
CURRENT VS 10Y AVG
+64.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.27%
median of 386 covered companies
CURRENT VS SECTOR MEDIAN
-8.14%
vs the sector median at left
Axsome Therapeutics, Inc.
Market Cap
$9.11B
Return on Assets (ROA)
-25.17%
TTM Avg
-38.54%
3Y Avg
-43.55%
5Y Avg
-63.00%
Market Cap
$9.35B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$9.39B
Return on Assets (ROA)
11.86%
TTM Avg
10.65%
3Y Avg
7.37%
5Y Avg
5.11%
Market Cap
$8.78B
Return on Assets (ROA)
-15.15%
TTM Avg
-26.36%
3Y Avg
-26.24%
5Y Avg
-23.50%
Market Cap
$9.60B
Return on Assets (ROA)
3.54%
TTM Avg
3.68%
3Y Avg
4.39%
5Y Avg
5.01%
Market Cap
$8.59B
Return on Assets (ROA)
8.55%
TTM Avg
-64.90%
3Y Avg
-64.30%
5Y Avg
-51.23%
Market Cap
$9.72B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$8.41B
Return on Assets (ROA)
4.91%
TTM Avg
-3.24%
3Y Avg
-6.85%
5Y Avg
-10.42%
Market Cap
$10.07B
Return on Assets (ROA)
6.44%
TTM Avg
6.68%
3Y Avg
6.69%
5Y Avg
12.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $9.11B | -25.17% | -38.54% | -43.55% | -63.00% |
| Bruker Corporation (BRKRP)vs › | $9.35B | -1.18% | 0.91% | 5.02% | 5.47% |
| Insulet Corp. (PODD)vs › | $9.39B | 11.86% | 10.65% | 7.37% | 5.11% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.78B | -15.15% | -26.36% | -26.24% | -23.50% |
| Henry Schein, Inc. (HSIC)vs › | $9.60B | 3.54% | 3.68% | 4.39% | 5.01% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.59B | 8.55% | -64.90% | -64.30% | -51.23% |
| Bruker Corporation (BRKR)vs › | $9.72B | -1.18% | 0.91% | 5.02% | 5.47% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 4.91% | -3.24% | -6.85% | -10.42% |
| Align Technology, Inc. (ALGN)vs › | $10.07B | 6.44% | 6.68% | 6.69% | 12.75% |
| The Ensign Group, Inc. (ENSG)vs › | $10.08B | 6.59% | 6.34% | 6.05% | 6.29% |
ROA
-25.2%
ROE
-230.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -26.55% |
| 2024-12-31 | -50.52% |
| 2023-12-31 | -40.67% |
| 2022-12-31 | -56.45% |
| 2021-12-31 | -148.55% |
| 2020-12-31 | -55.28% |
| 2019-12-31 | -30.99% |
| 2018-12-31 | -201.35% |
| 2017-12-31 | -81.40% |
| 2016-12-31 | -71.19% |
| 2015-12-31 | -24.88% |
| 2014-12-31 | -215.35% |
| 2013-12-31 | -103.30% |
